KA7

KA7 is a novel quinolone-based small molecule and sorafenib analogue, synthesized by replacing the urea component of sorafenib with a quinolone scaffold. It exhibits potent anticancer activity against breast cancer (MDA-231, MCF-7), glioblastoma (U87), and lung cancer (A549) cell lines, often showing superior or comparable efficacy to sorafenib in preclinical models. KA7 induces apoptosis, G1 phase cell cycle arrest, and autophagy. Additionally, it possesses an immunomodulatory profile, decreasing pro-inflammatory cytokines (IL-1β, TNF-α, and IL-6) and increasing anti-inflammatory cytokines (IL-8 and IL-10). It is currently being investigated as a promising lead chemical for further preclinical testing.

Other names

2-(4-chlorobenzylamino)-6-(pyridin-4-yloxy) quinolin-4(1H)-one